Once-Daily Use of Ofloxacin for Prophylaxis in Breast Cancer Surgery

Abstract

The 150 consecutive patients who were hospitalized for breast cancer at our department between September 1992 and November 1995 were enrolled in this open study after having given their informed consent. Patients were assigned randomly to receive ofloxacin in daily doses of 200 mg to be taken in a single dose or a total dose of 600 mg divided into three doses postoperatively for 5 days. Ten patients (8 found to be without malignancies) were excluded from evaluation. Wound infections developed in 8 (12%) of the 69 patients in the 200-mg group and 12 (17%) of the 71 patients in the 600-mg group. Postoperative wound care lasted a median of 19 days (25th and 75th percentiles, 15 and 29 days) for patients given 200 mg and 16 days (13 and 25 days) for those given 600 mg; the difference was not statistically significant (Wilcoxon’s U test). Signs or symptoms suggesting ofloxacin toxicity were not observed, and several significant differences were found in laboratory test results between the two groups both before and after treatment. Abnormal changes after treatment were found in many individuals, but the rate of occurrence was similar in the two groups (U test). When ofloxacin is used for prophylaxis after breast surgery, we recommend a once-daily administration of 200 mg orally for financial reasons and increased patient compliance.

Short Versus Long-term Postoperative Drainage of the Axilla After Axillary Lymph Node Dissection. A Prospective Randomized Study

“…Although ALND is a clean operation, infection rates as high as 19% have been reported [22][23][24] irrespective of the use of prophylactic antibiotics. Consistent with these reports, we found either a superficial or a deep infection in 17% of all patients.…”

Randomized clinical trial of single-dose antibiotic prophylaxis for non-reconstructive breast surgery

“…The reported incidence of wound infection after breast surgery is extremely variable, at between 1 and 30 per cent1–3. This is because of a lack of standard criteria for measuring wound infection, diverse periods of follow‐up and the inclusion of different types of operations and patients.…”

Hospital-Associated Costs Due to Surgical Site Infection After Breast Surgery

“…Surgical site infection rates have been reported to be lowest following breast-conserving surgery, ranging from 1.5% to 10.8%. [2][3][4][5][6][7][8] The incidence of SSI following mastectomy ranges from 2.8% to 25% in the surgical and infection control literature, [4][5][6][7][9][10][11][12][13][14][15][16][17][18] although only 2 studies 4,5 report an incidence of less than 5%. The SSI rate following breast cancer reconstructive surgery also seems to be relatively high (range, 6.3%-28%), based on a few reports in the literature.…”